B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

•4.8% of MS patients fulfilled defined criteria for COVID-19-suspect group.•Two patients required hospitalization; no intubation or ICU admission was reported.•Patients on B-cell depleting agents had higher risk of being in the COVID-19-suspect group. To determine whether the course of COVID-19 is m...

Celý popis

Podrobná bibliografia

Vydané v:	Multiple sclerosis and related disorders Ročník 43; s. 102195
Hlavní autori:	Safavi, Farinaz, Nourbakhsh, Bardia, Azimi, Amir Reza
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 01.08.2020
Predmet:	B-cell depleting therapies COVID-19 DMTs Multiple Sclerosis Multiple Sclerosis COVID-19 DMTs B-cell depleting therapies
ISSN:	2211-0348, 2211-0356, 2211-0356
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!